How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
Platelets Journal shared a post on LinkedIn about a recent article by Per Sandgren et al., adding:
“Recently published in Platelets!
‘Functionality of platelets after in vitro testing of pulsatile total artificial hearts’ by Per Sandgren, et al. (2026).
Haemolysis is a common regulatory endpoint for total artificial heart (TAH) haemocompatibility, however, little is known about resulting platelet function in these systems.
Having previously reported lower haemolysis with the Realheart TAH than with the FDA-approved SynCardia, Sandgren and colleagues circulated pooled human whole blood (n equal 5 per device) through the Realheart prototype (V11.2) and SynCardia for 360 minutes at 5 L/min and 100 mmHg under ASTM F1830, against static controls.
Most differences separated circulating from static blood, not one device from the other: static samples acidified, and
- CD42b, CD61, CD41, GPVI and PECAM-1 expression shifted with shear and surface contact.
Neither device raised CD62P or CD61-positive microparticles; JC-1 mitochondrial potential, PAC-1 responses to ADP and collagen, and EXTEM clot firmness were all preserved.
SynCardia alone raised mean platelet volume and lowered ATP at unchanged platelet counts, which the authors attribute to platelet-sized debris in the PRP fraction rather than platelet dysfunction, without measuring fragmentation directly.
Red cells and platelets appear to have different shear thresholds, though the authors frame these in vitro results as relative device effects rather than predictions of clinical outcome.
NB: The work was funded by Scandinavian Real Heart AB and all three authors are employees and/or shareholders.”
Title: Functionality of platelets after in vitro testing of pulsatile total artificial hearts
Authors: Per Sandgren, Shaikh Faisal Zaman, Ina Laura Perkins

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments
-
Nov 16, 2026, 12:44Stefan Prendić: How Intronic Variants Affect Rh Blood Group Antigen Expression
-
Nov 16, 2026, 12:26Samwel Mikaye: Understanding Warfarin and Its Clinical Management